Needham Rates Taysha Gene Therapies (TSHA) buy, $12 Price Target

Needham Maintains Buy Outlook on Taysha Gene Therapies Stock

Needham analyst Gil Blum reaffirmed a buy rating on Taysha Gene Therapies, Inc. (NasdaqGS: TSHA) on June 30, 2026, keeping the price target steady at $12. The rating update keeps the firm's positive stance unchanged as the clinical-stage biotech company continues its work on gene therapies for central nervous system disorders.

Taysha Gene Therapies Stock Trades Near 52-Week Highs

Taysha Gene Therapies shares changed hands at $6.81, sitting close to the upper end of its 52-week range that spans from a low of $2.87 to a high of $7.30. The stock continues to hold above key technical levels, including its 50-day moving average of $5.78 and its 200-day moving average of $5.48. The company carries a market capitalization of roughly $1.64 billion and a beta of 1.17.

Analysts Set New Price Targets

Several other firms have updated their outlooks on Taysha Gene Therapies alongside Needham's June 30 rating. On June 30, 2026, Baird maintained an Outperform rating and lifted its price target to $15 from $12. Earlier in the month, on June 23, 2026, BMO Capital maintained an Outperform rating while raising its price target to $14 from $10, and B of A Securities maintained a Buy rating with a target bumped to $10 from $9. Citizens also maintained a Market Outperform rating on June 23, 2026, with an increased target of $11. Goldman Sachs later added a maintain action on July 21, 2026, with a Buy rating and a $13 price target, while Wolfe Research initiated coverage with an Outperform rating on September 17, 2026. Across the wider analyst community, the stock holds a strong buy recommendation key with 13 analysts tracking the company and an average price target of $13.

Inside the Biotech Pipeline

Taysha Gene Therapies, Inc. focuses on developing adeno-associated virus-based gene therapies to treat severe monogenic central nervous system diseases. Its pipeline includes experimental treatments for conditions such as Rett syndrome, giant axonal neuropathy, and angelman syndrome. The Dallas-based firm works closely with research partners like The University of Texas Southwestern Medical Center.

What to Watch Next for TSHA

Investors will look toward the company's next earnings report, scheduled for November 4, 2026, for further updates on clinical progress and financial position. The firm reported revenue of $5.49 million over its recent tracking period alongside an earnings per share figure of -$0.41.